<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="101">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524679</url>
  </required_header>
  <id_info>
    <org_study_id>ML 27787</org_study_id>
    <nct_id>NCT01524679</nct_id>
  </id_info>
  <brief_title>Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen</brief_title>
  <acronym>PADD-ON</acronym>
  <official_title>A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys®)180 μg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomised, open-label phase IIb clinical trial assessing the effect of
      pegylated interferon alfa-2a(Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing
      nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B

      The primary objective of the trial is to investigate whether the add-on of pegylated
      interferon alfa-2a to a continued treatment with nucleos(t)ide analogues increases the
      percentage of patients who have significant decrease (≥ 1log10) of HBs antigen after 48
      weeks.

      170 Patients with chronic hepatitis B, HBe antigen negative, already being treated with an
      oral antiviral regimen and having a nondetectable viral load for at least 12 months are
      included.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Difference in percentage of patients between treatment and comparator arm reaching a ≥ 1log10 decline of quantitative HBsAg after 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference in percentage of patients between treatment and comparator arm reaching a ≥ 1log10 decline of quantitative HBsAg after 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decline of quantitative HBs antigen at week 12 and 24</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Decline of quantitative HBs antigen at week 12 and 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>ongoing nucleos(t)ide based treatment alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a plus nucleos(t)ide(s)</intervention_name>
    <description>Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Pegasys®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B, HBe antigen negative

          -  treatment with a stable oral antiviral treatment (not containing telbivudine) and a
             fully suppressed viral load for at least 12 months (below limit of detection in
             conventional HBV-PCR assays, i.e. &lt;116 IU / ml).

          -  18-70 ys

          -  willingness and ability to give informed consent and to follow study procedures

          -  willingness to use adequate contraception

        Exclusion Criteria:

          -  contraindications against treatment with pegylated interferon, e.g. depression,
             uncontrolled epilepsy, autoimmune diseases, pregnancy, leukocytopenia or
             thrombocytopenia at screening, etc.

          -  active alcohol or drug abuse

          -  preexisting polyneuropathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter R. Galle, Univ.-Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter R Galle, Univ.-Prof. Dr. med.</last_name>
    <phone>+49 6131 17</phone>
    <phone_ext>7275</phone_ext>
    <email>peter.galle@unimedizin-mainz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Grambihler, Dr. med.</last_name>
    <phone>+49 6131 17</phone>
    <phone_ext>6075</phone_ext>
    <email>annette.grambihler@unimedizin-mainz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Facharztpraxis Prof. Löhr</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65185</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanns Löhr, Prof. Dr. med.</last_name>
      <phone>0049 (0)611</phone>
      <phone_ext>377911</phone_ext>
      <email>loehr@gastroenterologie-wiesbaden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Medizinische Klinik III</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Tacke, PD Dr. med.</last_name>
      <phone>+49 241 808</phone>
      <phone_ext>0860</phone_ext>
      <email>ftacke@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow Klinikum, Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eckart Schott, Prof.Dr.med.</last_name>
      <phone>+49 30 450553</phone>
      <phone_ext>199</phone_ext>
      <email>eckart.schott@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leber- und Studienzentrum am Checkpoint</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renate Heyne, Dr. med.</last_name>
      <phone>+49 30 259 30</phone>
      <phone_ext>6470</phone_ext>
      <email>heyne@leberzentrum-checkpoint.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I, Universitätsklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Spengler, Prof.Dr.med.</last_name>
      <phone>+49 228 287</phone>
      <phone_ext>6789</phone_ext>
      <email>spengler@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Dr. Mauss, Schmutz, Dr. Athmann, Dr. Hegener</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Athmann, Dr. med.</last_name>
      <phone>+49 211 239</phone>
      <phone_ext>5520</phone_ext>
      <email>christoph.athmann@center-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik I, Klinik der J.W. Goethe Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Zeuzem, Prof.Dr.med.</last_name>
      <phone>+49 69 6301</phone>
      <phone_ext>5212</phone_ext>
      <email>zeuzem@em.uni-frankfurt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teuber Consulting &amp; Research KG</name>
      <address>
        <city>Frankfurt</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerlinde Teuber, PD Dr. med.</last_name>
      <phone>+49 0172</phone>
      <phone_ext>6062623</phone_ext>
      <email>gerlinde.teuber@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Innere Medizin II</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Thimme, Prof. Dr. med.</last_name>
      <phone>+49 761 270</phone>
      <phone_ext>34010</phone_ext>
      <email>robert-thimme@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Lohmeyer, Prof. Dr. med.</last_name>
      <phone>+49 641 985</phone>
      <phone_ext>57065</phone_ext>
      <email>thomas.discher@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, I. Med. Klinik und Poliklinik</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Cornberg, PD Dr. med.</last_name>
      <phone>+49 511 532</phone>
      <phone_ext>2730</phone_ext>
      <email>cornberg.markus@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Medizinische Klinik IV</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Pathil-Warth, Dr. med.</last_name>
      <phone>+49 6221 56</phone>
      <phone_ext>8388</phone_ext>
      <email>anita.pathil-warth@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Lammert, Prof. Dr.</last_name>
      <phone>+49 6841 16</phone>
      <phone_ext>23577</phone_ext>
      <email>karen.schneider@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Schleswig-Holstein Campus Kiel Klinik für Allgemeine Innere Medizin</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perdita Wietzke-Braun, PD Dr. med.</last_name>
      <phone>+49 431 5971</phone>
      <phone_ext>393</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Gastroenterologie und Hepatologie am Abdominalzentrum Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Goeser, Prof. Dr. med.</last_name>
      <phone>+49 221 478</phone>
      <phone_ext>7334</phone_ext>
      <email>tgoeser-studien@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Berg, Prof. Dr. med.</last_name>
      <phone>+49 341 97</phone>
      <phone_ext>12330</phone_ext>
      <email>thomas.berg@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, I. Med. Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter R Galle, Univ.-Prof.Dr.med.</last_name>
      <phone>+49 6131 17</phone>
      <phone_ext>7275</phone_ext>
      <email>Peter.Galle@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Ebert, Prof. Dr. med.</last_name>
      <phone>+49 621 383</phone>
      <phone_ext>3284</phone_ext>
      <email>sekretariat.med2@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian Geisler, PD Dr. med.</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>5972</phone_ext>
      <email>fabian.geisler@lrz.tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kilian Weigand, PD</last_name>
      <phone>+49 941 944 7030</phone>
      <email>kilian.weigand@ukr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Tübingen Innere Medizin Abt. I</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Berg, PD Dr. med.</last_name>
      <phone>+49 7071 2982</phone>
      <phone_ext>723</phone_ext>
      <email>christoph.berg@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Zentrum für Innere Medizin</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Dollinger, PD Dr. med.</last_name>
      <phone>+49 731 500</phone>
      <phone_ext>44609</phone_ext>
      <email>matthias.dollinger@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Würzburg Zentrum für Innere Medizin (ZIM) Medizinische Klinik und Poliklinik II Leber- und Infektionsambulanz</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartwig Klinker, Prof. Dr. med.</last_name>
      <phone>+49 931 201</phone>
      <phone_ext>40080</phone_ext>
      <email>klinker_H@ukw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Sprinzl MF, Grambihler A, Kittner JM, Wachtlin D, Ruckes C, et al. (2015) Prospective Randomized Open-label Trial Protocol Investigating the Addition of Pegylated Interferon-alpha to an Ongoing Nucleos(t)ide Treatment Regimen of HBeAg Negative Chronic Hepatitis B Patients (PADD-ON). J Clin Trials 5: 226. doi:10.4172/2167-0870.1000226</citation>
  </reference>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 30, 2015</lastchanged_date>
  <firstreceived_date>January 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Peter R. Galle</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis B</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
